An inhaled version of the antibiotic ciprofloxacin produced positive results in a Phase II trial studying its use in the treatment of bronchiectasis, a type of lung damage that can occur in people with cystic fibrosis and other lung diseases as a result of frequent lung infections. Earlier this week, Aradigm Corporation reported that single daily doses of inhaled liposomal ciprofloxacin hydrochloride (ILCH) given over a four week period significantly reduced the amount of Pseudomnas aeruginosa in the lungs of the study participants. This particular study of ILCH is being done on people whose bronchietasis is not related to cystic fibrosis, but the drug has been tested in the past on a small group of people with cystic fibrosis. In that study, single daily doses of ILCH produced equally positive results.
Related Articles:
